metformin has been researched along with FMR1-Related Primary Ovarian Insufficiency in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to assess the therapeutic effects of a well-known component (puerarin) obtained from a Chinese herb root in patients with polycystic ovary syndrome (PCOS)." | 9.41 | Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. ( Hu, H; Li, F; Li, W; Liu, J; Ma, Z; Zou, G, 2021) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 9.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| "This study aims to assess the therapeutic effects of a well-known component (puerarin) obtained from a Chinese herb root in patients with polycystic ovary syndrome (PCOS)." | 5.41 | Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. ( Hu, H; Li, F; Li, W; Liu, J; Ma, Z; Zou, G, 2021) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 5.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Navarro-Pando, JM | 1 |
| Bullón, P | 1 |
| Cordero, MD | 1 |
| Alcocer-Gómez, E | 1 |
| Li, W | 1 |
| Hu, H | 1 |
| Zou, G | 1 |
| Ma, Z | 1 |
| Liu, J | 1 |
| Li, F | 1 |
| Pan, ML | 1 |
| Chen, LR | 1 |
| Tsao, HM | 1 |
| Chen, KH | 1 |
| Wang, XH | 1 |
| Wang, JQ | 1 |
| Xu, Y | 1 |
| Huang, LP | 1 |
2 trials available for metformin and FMR1-Related Primary Ovarian Insufficiency
| Article | Year |
|---|---|
Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women.
Topics: Administration, Oral; Adolescent; Adult; China; Cholesterol; Cyproterone Acetate; Drug Administratio | 2021 |
Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Laparoscopy; Me | 2015 |
2 other studies available for metformin and FMR1-Related Primary Ovarian Insufficiency
| Article | Year |
|---|---|
Is AMP-Activated Protein Kinase Associated to the Metabolic Changes in Primary Ovarian Insufficiency?
Topics: AMP-Activated Protein Kinases; Biomarkers; Case-Control Studies; Disease Management; Disease Suscept | 2020 |
Polycystic ovarian syndrome and the risk of subsequent primary ovarian insufficiency: a nationwide population-based study.
Topics: Adolescent; Adult; Databases, Factual; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ov | 2017 |